Evidence map›Paper›PMID 35706127›Full record

ArticleCancer research2022

Developmental Pathways Are Epigenetically Reprogrammed during Lung Cancer Brain Metastasis.

Jennifer A Karlow, Siddhartha Devarakonda, Xiaoyun Xing, Hyo Sik Jang, Ramaswamy Govindan, Mark Watson, Ting Wang

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jennifer A KarlowDepartment of Genetics, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0001-5041-2669
Siddhartha DevarakondaDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Xiaoyun XingDepartment of Genetics, Washington University School of Medicine, St. Louis, Missouri.
Hyo Sik JangDepartment of Genetics, Washington University School of Medicine, St. Louis, Missouri.
Ramaswamy GovindanDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Mark WatsonDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-3935-9980
Ting WangDepartment of Genetics, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-6800-242X
Washington University in St. Louis · USJames S. McDonnell Foundation · US

Funding

Generation of novel cell type specific mouse genetic toolsU19MH114830 · NIMH · ALLEN INSTITUTE · PI NGAI, JOHN J. · 2017 to 2021
$64.7M
The WashU-UCSC-EBI Human Genome Reference Center."U41HG010972 · NHGRI · WASHINGTON UNIVERSITY · PI Ira M Hall, Heng Li · 2019 to 2026
$24.9M
GENCODE: comprehensive reference genome annotation for human and mouseU24HG007234 · NHGRI · EUROPEAN MOLECULAR BIOLOGY LABORATORY · PI Fergal James Martin · 2021 to 2026
$16.1M
WashU-Northwestern Genomic Variation and Function Data and Administrative Coordinating CenterU24HG012070 · NHGRI · WASHINGTON UNIVERSITY · PI Ting Wang, Feng Yue · 2021 to 2026
$9.7M
Center for Integrated Multi-modal and Multi-scale Nucleome ResearchUM1HG011585 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DULAC, CATHERINE, LEIN, ED · 2020 to 2024
$6.7M
MOLECULAR ONCOLOGY TRAINING GRANTT32CA113275 · NCI · WASHINGTON UNIVERSITY · PI Matthew J Walter · 2006 to 2026
$5.7M
THE WASHU TARGET ENVIRONMENTAL EPIGENOMICS DATA COORDINATION CENTERU24ES026699 · NIEHS · WASHINGTON UNIVERSITY · PI WANG, TING · 2016 to 2021
$5.2M
RESEARCH EDUCATION PROGRAM ON COMPUTATIONAL AND STATISTICAL TOOL DEVELOPMENT FOR ADDICTION GENETICSR25DA027995 · NIDA · WASHINGTON UNIVERSITY · PI MADDEN, PAMELA ANN, RICE, JOHN P. · 2009 to 2019
$4.3M
DECODING THE IMPACT OF TRANSPOSABLE ELEMENTS ON GENE REGULATIONR01HG007175 · NHGRI · WASHINGTON UNIVERSITY · PI WANG, TING · 2014 to 2021
$2.7M
Connecting transposable elements and regulatory innovation using ENCODE dataU01HG009391 · NHGRI · WASHINGTON UNIVERSITY · PI COHEN, BARAK A, FESCHOTTE, CEDRIC · 2017 to 2021
$2.4M
The WashU 4DN Network Data Coordination and Integration CenterU01CA200060 · NCI · WASHINGTON UNIVERSITY · PI WANG, TING · 2015 to 2019
$1.9M
GENOMIC HARBINGERS OF BRAIN METASTASIS IN NON SMALL CELL LUNG CANCERR01CA182746 · NCI · WASHINGTON UNIVERSITY · PI GOVINDAN, RAMASWAMY, WATSON, MARK A. · 2014 to 2018
$1.6M
NCI NIH HHS R01 CA182746NCI NIH HHS T32 CA113275NCI NIH HHS U01 CA200060NHGRI NIH HHS R01 HG007175NHGRI NIH HHS R01 HG007354NHGRI NIH HHS U01 HG009391NHGRI NIH HHS U24 HG007234NHGRI NIH HHS U24 HG012070NHGRI NIH HHS U41 HG010972NHGRI NIH HHS UM1 HG011585NIDA NIH HHS R25 DA027995NIEHS NIH HHS R01 ES024992NIEHS NIH HHS U24 ES026699NIMH NIH HHS U19 MH114830
6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed and deadliest cancers worldwide, with roughly half of all patients initially presenting with both primary and metastatic disease. While the major events in the metastatic cascade have been identified, a mechanistic understanding of how NSCLC routinely and successfully colonizes the brain is largely unknown. Recent studies have begun demonstrating the role of epigenetic misregulation during tumorigenesis and metastasis, including widespread changes in DNA methylation and histone modifications. To better understand the role of altered DNA methylation in NSCLC metastasis to the brain, we measured DNA methylation during disease progression for 12 patients, globally profiling the methylation status of normal lung, primary lung tumor, and brain metastasis samples. The variation in methylation was similar during metastatic spread and primary tumorigenesis but less coordinated across genomic features during metastasis. The greatest recurrent changes during metastatic progression were methylation gains in DNA methylation valleys (DMV) harboring the constitutive heterochromatin mark H3K9me3 as well as bivalent marks H3K27me3 and H3K4me1. In a lymph node-derived cancer cell line, EZH2 binding within DMVs was lost, accompanied by an increase in DNA methylation, exemplifying epigenetic switching. The vast majority of the differentially methylated region-associated DMVs harbored developmental genes, suggesting that altered epigenetic regulation of developmentally important genes may confer a selective advantage during metastatic progression. The characterization of epigenetic changes during NSCLC brain metastasis identified recurrent methylation patterns that may be prognostic biomarkers and contributors to disease progression. SIGNIFICANCE: Altered DNA methylation in lung cancer brain metastases corresponds with loss of EZH2 occupancy at developmental genes, which could promote stem-like phenotypes permissive of dissemination and survival in different microenvironments.

Indexed as

Brain NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsCarcinogenesisDisease ProgressionDNA MethylationEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansTumor Microenvironment

Identifiers

PMID35706127
PMCPMC9357144
OpenAlexW4283015173

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.